Loading patent…
AssigneeThe Trustees of the University of Pennsylvania
InventorsRuxandra Draghia-Akli, David B Weiner, Jian Yan, Dominick J Laddy
Estimating the term…
An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.
A DNA plasmid vaccine capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising:
A DNA plasmid comprising a coding sequence operably linked to a promoter which functions in a cell of a mammal, wherein the coding sequence encodes consensus influenza antigen hemagglutinin (HA) subtype H1 and comprises SEQ ID NO:9.
A DNA molecule comprising a nucleotide sequence comprising SEQ ID NO:9 or a fragment thereof that is an at least 1380 or more nucleotide fragment of SEQ ID NO:9.
Dependencies are inferred from the claim text.